5395242026-09-245395242026-09-242026-09-245395242026-09-24in-capmkt:FinancialYear1Member5395242026-09-24in-capmkt:FinancialYear2Member5395242026-09-24in-capmkt:FinancialYear3Member5395242026-09-242026-09-24in-capmkt:FinancialYear1Member5395242026-09-242026-09-24in-capmkt:FinancialYear2Member5395242026-09-242026-09-24in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure539524Dr. Lal Path Labs Ltd.LALPATHLABNOTLISTEDINE600L01024NewAcquisition (including agreement to acquire)true2026-09-2417:11:002026-09-24Acquisition of 70% stake in SN Genelab Private Limited (“SN Gene”) from its existing Shareholders. Post acquisition, SN Gene shall become a Subsidiary of the Company.Dr. Lal Path Labs Ltd.Listed Entity (self)SN Genelab Private Limited57960000052300000329000000falsefalsetrueDiagnostics - GenomicsTo strengthen the Company’s expertise in genomics and broaden its portfolio of advanced diagnostic services.NAfalse30-11-2026Cash1680000000The consideration is upto INR 168 Crores plus certain performance linked earn out capped at INR 31.5 Crores for 70% stake, which will be paid as per terms of the agreement168000000000.7SN Gene was incorporated on December 16, 2013 in the State of Gujarat and is engaged in business of providing Diagnostics - Genomics services.2025-20265796000002024-20255336000002023-2024432700000IndiaThe aforementioned acquisition does not qualify as a related party transaction. However, due to limitations in the XBRL format, the question, Whether the transaction was conducted at arm's length, provides only a Yes/No dropdown option. We selected Yes; however, this should be interpreted as Not Applicable.